RTI SURGICAL, INC. (NASDAQ:RTIX) Files An 8-K Results of Operations and Financial Condition

RTI SURGICAL, INC. ExhibitEX-99.1 2 d601631dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Press Release    RTI Surgical Announces Second Quarter 2018 Results Performance Powered by Ongoing Strength of OEM Business and Operational Excellence Initiatives Highlights:     •   Second Quarter 2018 revenue of $70.7 million     •   Second Quarter 2018 Net loss of $6.4 million,…To view the full exhibit click here
About RTI SURGICAL, INC. (NASDAQ:RTIX)
RTI Surgical, Inc. is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties. It processes donated human musculoskeletal and other tissue, including bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine and porcine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE, TUTOPLAST and CANCELLE SP sterilization processes, and manufactures metal and synthetic implants for distribution to hospitals and surgeons. The Company distributes its implants and services in approximately 50 states and in over 45 countries across the world.